Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Next Previous
Trial Profile

An Open-label, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms Study 217
  • Sponsors Eisai Co Ltd

Most Recent Events

  • 26 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 29 Feb 2016 According to an Eisai media release, based on the results of this trial, eribulin mesylate (Halaven) received approval in Japan for use in the treatment of patients with soft tissue sarcoma.
  • 15 Jul 2014 Planned End Date changed from 1 Jan 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top